There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Mayne Pharma Group Limited (MAYNF – Research Report) and Mesoblast Limited (MEOBF – Research Report) with bullish sentiments.
Mayne Pharma Group Limited (MAYNF)
In a report issued on August 16, Martyn Jacobs from Canaccord Genuity maintained a Buy rating on Mayne Pharma Group Limited, with a price target of A$0.51. The company’s shares closed last Wednesday at $0.25.
According to TipRanks.com, Jacobs is a 1-star analyst with an average return of
Currently, the analyst consensus on Mayne Pharma Group Limited is a Moderate Buy with an average price target of $0.30, implying a 9.6% upside from current levels. In a report issued on August 8, Wilsons also maintained a Buy rating on the stock with a A$0.32 price target.
See today’s best-performing stocks on TipRanks >>
Mesoblast Limited (MEOBF)
Bell Potter analyst John Hester maintained a Buy rating on Mesoblast Limited on August 16 and set a price target of A$1.70. The company’s shares closed last Thursday at $0.64.
According to TipRanks.com, Hester is a 4-star analyst with an average return of
Currently, the analyst consensus on Mesoblast Limited is a Moderate Buy with an average price target of $1.18.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on MAYNF:
